Approved, compounded, and unapproved: why the distinction matters
A plain-language guide to product status, quality review, and avoiding false equivalence.
Educational information only — not medical advice. This page does not diagnose conditions, recommend treatment, or replace care from a qualified clinician. The Peptide Center uses an evidence-first editorial process: regulatory sources, trial registries, and peer-reviewed research take priority; uncertainty is stated rather than filled with promises.
FDA approval applies to a specific product for specific labeled uses. Compounded drugs are not FDA approved, and an unapproved product has not undergone FDA review as a complete product for safety, effectiveness, and quality. These categories should not be treated as interchangeable.
References
Related resources
Continue with curated, same-topic resources from the published library. These links are educational references, not treatment recommendations.
FDA approved, compounded, and unapproved are not synonyms
A plain-language map of product categories that are often blurred in peptide discussions.
Open resourceArticleHow to read a peptide study without overclaiming
A practical guide to research stage, controls, endpoints, uncertainty, and applicability.
Open resourceArticlePreparing for a peptide conversation with a clinician
A neutral question list for discussing goals, evidence, product status, and uncertainty.
Open resourceArticleA clinical-trial record is not proof that a peptide works
What a trial registry can tell you, what it cannot, and how to avoid overreading a study status.
Open resourceArticleAn ingredient name is not a complete product
Why matching a molecule name does not establish sameness in approval, formulation, quality, or evidence.
Open resourceArticleWhy a biological mechanism is not a treatment promise
A practical explanation of why plausible pathways still need meaningful human-outcome evidence.
Open resource